Home › Funds › TANG CAPITAL MANAGEMENT LLC › LKFT

TANG CAPITAL MANAGEMENT LLC position in LKFT

LAKEFRONT BIOTHERAPEUTICS NV

TANG CAPITAL MANAGEMENT LLC reported holding 3,785,991 shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV) in its Q2 2026 13F filing — a position valued at US$113.5M, representing 5.16% of its reported portfolio and ranking #8 among its reported holdings. TANG CAPITAL MANAGEMENT LLC has disclosed LKFT holdings in 10 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)3.79M sh
Reported value held$113.50M
Portfolio Weight5.16%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How TANG CAPITAL MANAGEMENT LLC's LKFT position evolved

TANG CAPITAL MANAGEMENT LLC first disclosed a stake in LKFT in Q3 2023 at 89,650 shares (US$3.1M). The position peaked in Q3 2025 at 4,151,194 shares, worth US$143.8M. Across 10 filings, TANG CAPITAL MANAGEMENT LLC increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 3,785,991 shares valued at US$113.5M. Notable position changes include a 1159% increase in Q3 2024 (shares fell 4% over the following quarter), a 209% increase in Q4 2024 (shares fell 9% over the following quarter), a 83% increase in Q1 2025 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 89.65K $3.10M New
Q2 2024 55.61K $1.38M New
Q3 2024 700.00K $20.15M Add
Q4 2024 2.16M $59.43M Add
Q1 2025 3.96M $99.52M Add
Q2 2025 3.99M $111.68M Add
Q3 2025 4.15M $143.80M Add
Q4 2025 3.92M $128.22M Reduce
Q1 2026 3.79M $113.58M Reduce
Q2 2026 3.79M $113.50M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LKFT and 13F data

LKFT (LAKEFRONT BIOTHERAPEUTICS NV) is a company whose sector is not yet classified in our data. 17 other funds we track also report a position in LKFT — the largest reported positions include GILEAD SCIENCES, INC. (US$500.2M), Madison Avenue Partners, LP (US$103.4M), Prosight Management, LP (US$61.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LKFT

All LKFT fund holders →

FAQ

How long has TANG CAPITAL MANAGEMENT LLC held LKFT?

TANG CAPITAL MANAGEMENT LLC has disclosed LKFT holdings in 10 of the last 12 reported quarters, going back to Q3 2023.

What is TANG CAPITAL MANAGEMENT LLC's current position in LKFT?

As of Q2 2026, TANG CAPITAL MANAGEMENT LLC holds 3.79M shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV), valued at $113.50M, representing 5.16% of its reported portfolio and ranking #8.

Has TANG CAPITAL MANAGEMENT LLC been buying or selling LKFT?

In the latest 13F filing (Q2 2026), TANG CAPITAL MANAGEMENT LLC held unchanged its position in LKFT. The position peaked in Q3 2025 at 4.15M shares.

Which other funds hold LKFT?

Other major institutional holders of LKFT include GILEAD SCIENCES, INC., Madison Avenue Partners, LP, Prosight Management, LP, among 17 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.